... and now a paper on treatment. But note that this is only relevant for a very, very small number of people - literally one in a million.
The drug has an interesting history: as you can see this paper was published over 15 years ago. Until recently the drug was owned by Astra Zeneca. They didn't want to put in the substantial effort of time and money needed to market the drug commercially, and so (to their credit) provided the drug free to some clinics. But recently they sold the rights to Aegerion who secured FDA approval and have launched Metreleptin commercially in the USA. It's not cheap.